• 1
    Skelly MM, Hawkey CJ (2003) Dual COX inhibition and upper gastrointestinal damage. Curr Pharm Des 9, 21915.
  • 2
    Simon LS, Weaver AL, Graham DY et al. (1999) Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. JAMA 282, 19218.
  • 3
    Mamdani M, Rochon PA, Juurlink DN et al. (2002) Observational study of upper gastrointestinal hemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325, 624.
  • 4
    Rang HP, Dale MM, Ritter JM (2000) Non steroidal anti-inflammatory drugs. In: Pharmacology 4th edn. pp. 22935. New York: Churchill Livingstone.
  • 5
    Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ (2000) Cyclooxygenase-1 and 2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102, 8405.
  • 6
    Bombardier C, Laine L, Reicin A et al. (2000) Comparison of upper gastrointestinal toxicity of Rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 343, 15208.
  • 7
    Bresalier RS, Sandler RS, Quan H et al. (2005) Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352, 1092102.
  • 8
    Panwar RB, Gupta R, Gupta BK et al. (2011) Atherothrombotic risk factors and premature coronary heart disease in India: a case control study. Indian J Med Res 134, 2632.
  • 9
    Maradit-Kremers H, Crowson CS, Nicola PJ et al. (2005) Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52, 40211.
  • 10
    Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. J Rheumatol 33, 216772.
  • 11
    Symmons DP, Gabriel SE (2011) Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 7, 399408.
  • 12
    Layton D, Heeley E, Hughes K, Shakir SA (2003) Comparison of the incidence rates of thromboembolic events reported for patients prescribed Rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology 42, 134253.
  • 13
    Becker JC, Domschke W, Pohle T (2004) Current approaches to prevent NSAID-induced gastropathy – COX selectivity and beyond. Br J Clin Pharmacol 58, 587600.
  • 14
    Pincus T, Koch G, Lei H et al. (2004) Patient preference for placebo, acetaminophen (paracetamol) or Celecoxib efficacy studies (PACES): two randomized, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 63, 9319.
  • 15
    Greenberg JD, Fisher MC, Kremer J et al. (2009) The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clin Exp Rheumatol 27, 395401.
  • 16
    Capone ML, Tacconelli S, Sciulli MG, Patrignani P (2003) Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopath Pharmacol 16, 4958.
  • 17
    Hegazy R, Alashhab M, Amin M (2011) Cardiorenal effects of newer NSAIDs (Celecoxib) versus classic NSAIDs (Ibuprofen) in patients with arthritis. J Toxicol doi:10.1155/2011/862153.
  • 18
    Whelton A, Lefkowith JL, West CR, Verburg KM (2006) Cardiorenal effects of Celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int 70, 1495502.
  • 19
    Muscara MN, Vergnolle N, Lovren F et al. (2000) Selective cyclo-oxygenase-2 inhibition with Celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 129, 142330.
  • 20
    White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A (2002) Effects of Celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 39, 92934.
  • 21
    Solomon SD, Pfeffer MA, McMurray JJ et al. (2006) Effect of Celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114, 102835.
  • 22
    Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB (2000) Basic biology and clinical application of specific cyclo-oxygenase-2 inhibitors. Arthritis Rheum 43, 413.
  • 23
    Schwartz JI, Vandormael K, Malice MP et al. (2002) Comparison of Rofecoxib, Celecoxib and naproxen on renal function in elderly subjects receiving a normal salt diet. Clin Pharmacol Ther 72, 5061.
  • 24
    Steffel J, Hermann M, Greutert H et al. (2005) Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Clin Circulation 111, 16859.